MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/infdis/jiad434

Медицинская библиотека · The Journal of infectious diseases · 2024

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.

Chirenje Zvavahera Mike, Laher Fatima, Dintwe One, Muyoyeta Monde, deCamp Allan C, He Zonglin, Grunenberg Nicole, Laher Omar Faatima, Seaton Kelly E, Polakowski Laura, Woodward Davis Amanda S, Maganga Lucas, Baden Lindsey R, Mayer Kenneth, Kalams Spyros, Keefer Michael, Edupuganti Srilatha, Rodriguez Benigno, Frank Ian, Scott Hyman, Stranix-Chibanda Lynda, Gurunathan Sanjay, Koutsoukos Marguerite, Van Der Meeren Olivier, DiazGranados Carlos A, Paez Carmen, Andersen-Nissen Erica, Kublin James, Corey Lawrence, Ferrari Guido, Tomaras Georgia, McElrath M Juliana

СтатьяРандомизированное исследованиеКлиническое исследование II фазыКлиническое исследование I фазыПеревод в очереди

Аннотация

BACKGROUND

HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults.

METHODS

Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses.

RESULTS

We enrolled 160 participants, 55% women, 18-40 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40 μg gp120/AS01B group were higher than in either of the 200 μg gp120 groups.

CONCLUSIONS

The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses. Clinical Trials Registration . NCT03122223.

Для цитирования: Chirenje Zvavahera Mike, Laher Fatima, Dintwe One, Muyoyeta Monde, deCamp Allan C, He Zonglin, Grunenberg Nicole, Laher Omar Faatima, Seaton Kelly E, Polakowski Laura, Woodward Davis Amanda S, Maganga Lucas, Baden Lindsey R, Mayer Kenneth, Kalams Spyros, Keefer Michael, Edupuganti Srilatha, Rodriguez Benigno, Frank Ian, Scott Hyman, Stranix-Chibanda Lynda, Gurunathan Sanjay, Koutsoukos Marguerite, Van Der Meeren Olivier, DiazGranados Carlos A, Paez Carmen, Andersen-Nissen Erica, Kublin James, Corey Lawrence, Ferrari Guido, Tomaras Georgia, McElrath M Juliana. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.. The Journal of infectious diseases. 2024. DOI: 10.1093/infdis/jiad434.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.